Edition:
United Kingdom

Ophthotech says Fovista phase 3 trial did not meet primary endpoint


Monday, 12 Dec 2016 

Ophthotech Corp : pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal phase 3 clinical trials . addition of Fovista to monthly Lucentis regimen did not result in benefit as measured by mean change in visual acuity at 12 month time point . based on preliminary analysis of safety data, Fovista and Lucentis monotherapy were generally well tolerated after one year of treatmen .Ophthotech announces results from pivotal phase 3 trials of Fovista in wet age-related macular degeneration.